BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19881343)

  • 1. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.
    Koo HL; DuPont HL
    Curr Opin Gastroenterol; 2010 Jan; 26(1):17-25. PubMed ID: 19881343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.
    DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
    Ann Intern Med; 2005 May; 142(10):805-12. PubMed ID: 15897530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
    Gerard L; Garey KW; DuPont HL
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin: a nonabsorbed oral antibiotic.
    Baker DE
    Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
    Cottreau J; Baker SF; DuPont HL; Garey KW
    Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
    Adachi JA; DuPont HL
    Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What's new in enteric infectious diseases at home and abroad.
    DuPont HL
    Curr Opin Infect Dis; 2005 Oct; 18(5):407-12. PubMed ID: 16148527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea.
    Steffen R
    J Travel Med; 2001 Dec; 8(Suppl 2):S34-9. PubMed ID: 12186672
    [No Abstract]   [Full Text] [Related]  

  • 9. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.
    Infante RM; Ericsson CD; Jiang ZD; Ke S; Steffen R; Riopel L; Sack DA; DuPont HL
    Clin Gastroenterol Hepatol; 2004 Feb; 2(2):135-8. PubMed ID: 15017618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.
    Taylor DN; Bourgeois AL; Ericsson CD; Steffen R; Jiang ZD; Halpern J; Haake R; Dupont HL
    Am J Trop Med Hyg; 2006 Jun; 74(6):1060-6. PubMed ID: 16760520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin for the treatment of acute infectious diarrhea.
    Hong KS; Kim JS
    Therap Adv Gastroenterol; 2011 Jul; 4(4):227-35. PubMed ID: 21765867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifaximin--a novel antimicrobial for enteric infections.
    Huang DB; DuPont HL
    J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis.
    Alajbegovic S; Sanders JW; Atherly DE; Riddle MS
    Syst Rev; 2012 Aug; 1():39. PubMed ID: 22929178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin: a new treatment for travelers' diarrhea.
    Pakyz AL
    Ann Pharmacother; 2005 Feb; 39(2):284-9. PubMed ID: 15598963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Hu Y; Ren J; Zhan M; Li W; Dai H
    J Travel Med; 2012 Dec; 19(6):352-6. PubMed ID: 23379704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.
    Dupont HL; Jiang ZD; Belkind-Gerson J; Okhuysen PC; Ericsson CD; Ke S; Huang DB; Dupont MW; Adachi JA; De La Cabada FJ; Taylor DN; Jaini S; Martinez Sandoval F
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):451-6. PubMed ID: 17382603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of rifaximin in gastrointestinal and liver diseases.
    Shayto RH; Abou Mrad R; Sharara AI
    World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of travelers' diarrhea with rifaximin on various continents.
    Steffen R; Sack DA; Riopel L; Jiang ZD; Stürchler M; Ericsson CD; Lowe B; Waiyaki P; White M; DuPont HL
    Am J Gastroenterol; 2003 May; 98(5):1073-8. PubMed ID: 12809830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey.
    Armstrong AW; Ulukan S; Weiner M; Mostafa M; Shaheen H; Nakhla I; Tribble DR; Riddle MS
    J Travel Med; 2010; 17(6):392-4. PubMed ID: 21050319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment.
    Okhuysen PC
    Curr Opin Infect Dis; 2005 Dec; 18(6):522-6. PubMed ID: 16258326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.